The measures would impose taxes on increases in the price of drugs that don’t reflect improved clinical value and set the rates paid by state-run and commercial health plans to a benchmark based on prices in Canada.
This article is for premium subscribers. Please sign up here for a tax-deductible subscription.
If you're a premium subscriber, sign in below.
An Oregon program that aims to peel back the opaque layers of prescription drug pricing wrapped up its first year this week with a report to the Legislature that underlines
While prescription costs continue rising faster than other healthcare expenses, some in the research industry contend that since drugs comprise a smaller portion of the overall cost, their impact has been overstated.